Per a March 3, 2026 FDA press announcement (FDA.gov press announcement, March 3, 2026), the FDA issued warning letters to 30 telehealth companies specifically for making claims that implied sameness with FDA-approved products
Within days to weeks of stopping treatment, patients generally experience return of appetite to pre-treatment levels, faster gastric emptying, and loss of the medication's effects on satiety signaling
As technologies like AI-powered triage and remote monitoring evolve, the role of telehealth in chronic disease management will only expand
However, the restrictions around taking oral semaglutide are burdensome
These companies have a strong presence in the region, with extensive distribution networks and robust marketing strategies, which support market growth in the country
A more complete plateau, when the scale essentially stops moving, typically arrives between 12 and 18 months for most patients, though a small proportion will continue losing weight for up to two years